-
Trizivir and Zymaxid generics' contribution will remain high going ahead, S Ramesh, CFO, Lupin said.
-
Speaking to CNBC-TV18, Ramesh Swminathan, CFO of Lupin says that the US, India and Japan markets continue to lead growth for the company.
-
Lupin's Q2 numbers were in line with street estimates, with margins slightly higher. MD Nilesh Gupta believes the company is back on its growth trajectory and will post better numbers going forward.
-
After receiving the USFDA nod for its supplemental new drug application for Antara capsules on Tuesday, Lupin will now focus on building back its brand by gaining its lost market share.
-
According to Kamal Sharma, Lupin should perform better in Q2 than Q1 and eyes double digit growth as against virtually no growth in Q1.
-
In an interview to CNBC-TV18, Sharma credits the foreign exchange for about 2 percent EBITDA growth in the company‘s earnings.
-
India is much tough market than US due to bureaucratic and regulatory uncertainties, says Vinita Gupta, Group President and CEO Lupin. But, the company aims to be a USD 5 billion company by 2017-18.
-
Lupin's S Ramesh expects 15-20 percent growth for FY14 on year-on-year basis. Going ahead, he believes the overall momentum would continue and the company will find growth.
-
Lupin wants to step in the next phase of growth by transforming itself in to a speciality company, plans to pump more of its branded products going forward.
-
Kamal Sharma, MD, Lupin Ltd says, in an interview to CNBC-TV18, that the attention to margins, quality and control on costs caused fourth-quarter net to double
-
Pharma major Lupin expects sales in the US to touch at least USD 150 million per quarter going ahead, S Ramesh, CFO, said on Tuesday.
-
S Ramesh, CFO, Lupin says that the Novartis judgment will not impact market much and it is a positive for domestic pharmaceutical sector. In an interview to CNBC-TV18, he adds, "No company can think of ignoring the Indian market and I do not see MNCs going slow on investment in India."
-
S Ramesh, CFO, Lupin, says that the company has received approval for Suprax drops. He also believes that the drop could help in expanding the market for Suprax. Suprax has gross sales of about USD 800 million and ranges across various strengths.
-
In an interview to CNBC-TV18, Kamal Sharma, managing director, Lupin gives his reaction on the company's positive Q3 results. The company's results beat expectations with itts profits jumping 43% to Rs 335 crore.
-
Lupin had a good year in the stock market. In an interview to CNBC-TV18, S Ramesh, president - finance & planning of Lupin says in the first two quarters of the current year, the company has exhibited more than 30 percent growth. "We are fairly confident that we will be able to sustain this in the next couple of quarters," he asserts.
-
Pharmaceutical company Lupin has become the latest entrant to the Nifty and will be indexed from September 28. The stock has been an outperformer over the months and S Ramesh, CFO of Lupin expects the company's domestic growth to be maintained at 22-25%.
-
Kamal Sharma, MD, Lupin explains to CNBC-TV18 that the 44% growth in the topline was driven primarily by the excellent performance of generics, launch of new products in the US, Japan and India, and the recent signing of a pact to launch Novartis‘ Onbrez brand for asthama.
-
Lupin‘s CFO S Ramesh tells CNBC-TV18 that he anticipates strong growth in FY13-14 from US.
-
Higher tax expenses led to a decline in consolidated net profit of pharma company, Lupin in the fourth quarter of FY12. The company posted a decline of 31% year-on-year to Rs 156 crore. However, net sales were up 25% between January-March at Rs 1,883.2 crore.
-
In an interview to CNBC-TV18, Dr Kamal K Sharma, managing director, Lupin said, the company will be able to maintain its performance during the year.
-
Lupin had launched Fortamet, a diabetic drug, at risk in the US, causing an injunction against the drug. Chief Financial Officer S Ramesh clarified that Fortamet generic was launched only for few days.
-
Speaking to CNBC-TV18, chief financial officer, S Ramesh, says that the acquisition of I'rom Pharmaceuticals will help increase Lupin's revenues from Japan to USD 250 million.
-
Lupin has recorded 24% growth in revenues as well as profit over the second quarter of the current financial year. Kamal K Sharma, managing director of Lupin joins CNBC-TV18 to highlight the key performance points and talk of the way forward for the company.
-
Kamal Sharma, managing director, Lupin in an interview with CNBC-TV18 said, growth in this quarter was driven by markets in India, Japan and South Africa.
-
Lupin, which has been a hot favourite among market experts, is growing ambitious. The drug company is eyeing to launch around 100 more products in the next two to three years.
